Atlas Trials

Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer.

Clinical trial NCT05378204 · RECRUITING

Trial details

NCT number
NCT05378204
Sponsor
Institut Claudius Regaud
Status
RECRUITING
Phase
Not Applicable
Study type
INTERVENTIONAL
Breast Cancer
Start date
2022-06-23
Primary completion
2027-01-01
Enrollment
120

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.